LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Lapatinib | 0.37 | uM | LJP6 | 1 | M22 | 72 | hr | 2543 | 2115 | 5578 | 0.3791 | -0.1412 |
| SK-BR-3 | Lapatinib | 0.37 | uM | LJP6 | 2 | M22 | 72 | hr | 2543 | 2270 | 5578 | 0.4069 | -0.0901 |
| SK-BR-3 | Lapatinib | 0.37 | uM | LJP6 | 3 | M22 | 72 | hr | 2543 | 2173 | 5578 | 0.3895 | -0.1221 |
| SK-BR-3 | LDN-193189 | 0.37 | uM | LJP5 | 1 | G04 | 72 | hr | 2543 | 6122 | 5578 | 1.0974 | 1.1790 |
| SK-BR-3 | LDN-193189 | 0.37 | uM | LJP5 | 2 | G04 | 72 | hr | 2543 | 5915 | 5578 | 1.0603 | 1.1108 |
| SK-BR-3 | LDN-193189 | 0.37 | uM | LJP5 | 3 | G04 | 72 | hr | 2543 | 5922 | 5578 | 1.0615 | 1.1131 |
| SK-BR-3 | Linifanib | 0.37 | uM | LJP6 | 1 | J10 | 72 | hr | 2543 | 5577 | 5578 | 0.9997 | 0.9995 |
| SK-BR-3 | Linifanib | 0.37 | uM | LJP6 | 2 | J10 | 72 | hr | 2543 | 5312 | 5578 | 0.9522 | 0.9121 |
| SK-BR-3 | Linifanib | 0.37 | uM | LJP6 | 3 | J10 | 72 | hr | 2543 | 5968 | 5578 | 1.0698 | 1.1283 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 1 | O22 | 72 | hr | 2543 | 5190 | 5578 | 0.9303 | 0.8720 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 2 | O22 | 72 | hr | 2543 | 5085 | 5578 | 0.9115 | 0.8374 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 3 | O22 | 72 | hr | 2543 | 5489 | 5578 | 0.9839 | 0.9705 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP5 | 1 | C22 | 72 | hr | 2543 | 1727 | 5578 | 0.3096 | -0.2690 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP5 | 2 | C22 | 72 | hr | 2543 | 1720 | 5578 | 0.3083 | -0.2713 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP5 | 3 | C22 | 72 | hr | 2543 | 1906 | 5578 | 0.3417 | -0.2100 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP6 | 1 | C22 | 72 | hr | 2543 | 1390 | 5578 | 0.2492 | -0.3800 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP6 | 2 | C22 | 72 | hr | 2543 | 1415 | 5578 | 0.2536 | -0.3718 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP6 | 3 | C22 | 72 | hr | 2543 | 1408 | 5578 | 0.2524 | -0.3741 |
| SK-BR-3 | MK2206 | 0.37 | uM | LJP6 | 1 | F04 | 72 | hr | 2543 | 3614 | 5578 | 0.6478 | 0.3527 |
| SK-BR-3 | MK2206 | 0.37 | uM | LJP6 | 2 | F04 | 72 | hr | 2543 | 3823 | 5578 | 0.6853 | 0.4216 |
| SK-BR-3 | MK2206 | 0.37 | uM | LJP6 | 3 | F04 | 72 | hr | 2543 | 3717 | 5578 | 0.6663 | 0.3866 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 1 | A16 | 72 | hr | 2543 | 1430 | 5578 | 0.2563 | -0.3669 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 2 | A16 | 72 | hr | 2543 | 1522 | 5578 | 0.2728 | -0.3365 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 3 | A16 | 72 | hr | 2543 | 1606 | 5578 | 0.2879 | -0.3089 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 1 | N16 | 72 | hr | 2543 | 6457 | 5578 | 1.1574 | 1.2894 |